首页> 外文会议>Chinese peptide symposium >A novel serie of ET_A selective antagonists
【24h】

A novel serie of ET_A selective antagonists

机译:Et_A选择性拮抗剂的一部小说Serie

获取原文

摘要

The endothelins (ETs) are a family of three isopeptides (ET-1, ET-2 and Et-3) with potent vasoconstrictor properties [1]. All three of these peptides are encoded in the human genome and each is composed of 21 amino acids, with disulfide linkages between cysteine residues at positions 1,15 and 3,11. The ETs elicit their effects through binding to receptors of the G-protein coupled seven-transmembrane spanning superfamily. Two receptor subtypes have thus far been fully characterized from human tissues through molecular cloning and expression. Recently, compelling data has become available using receptor specific antagonists to support a role for the ETs in disease processes. Despite extensive animal model studies, however, controversy still surrounds the optimal antagonist selectivity considered necessary for the treatment of human disorders [2] and this may also be dependent upon the disease targeted.
机译:内皮素(ETE)是三种异肽(ET-1,ET-2和ET-3)的家族,具有有效的血管电机特性[1]。这些肽中的所有三种在人类基因组中编码,每个肽由21个氨基酸组成,在1,15和3,11,111的半胱氨酸残基之间具有二硫键。 ETS通过与跨家族的G-蛋白偶联的七跨膜的受体结合来引发它们的效果。到目前为止,两种受体亚型通过分子克隆和表达完全表征了人体组织。最近,使用受体特异性拮抗剂可获得引人注目的数据,以支持疾病过程中ETS的作用。然而,尽管具有广泛的动物模型研究,但争议仍然围绕着治疗人类疾病所需的最佳拮抗剂选择性[2],这也可能取决于靶向的疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号